STORAGE: Mitoxantrone should be stored at room temperature, 15 C to 25 C (59 F to 77 F). It should not be frozen.
DOSING: Mitoxantrone is given by intravenous infusion. The recommended dose for secondary progressive multiple sclerosis is 12 mg/m2 infusion every 3 months. The lifetime cumulative dose is 140 mg/m2. The dose for nonlymphocytic leukemia is 12 mg/m2/day on days 1-3 with cytarabine 100 mg/m2/day on days 1-7. The dose for hormone-refractory prostate cancer is 12 to 14 mg/m2 every 21 days.
DRUG INTERACTIONS: Combining mitoxantrone with other drugs that, like mitoxantrone, suppress the immune system leads to severe immune suppression and an increased risk of infections.
PREGNANCY: Mitoxantrone should not be administered to pregnant women due to risk of severe harm to the fetus.
NURSING MOTHERS: Mitoxantrone is excreted in breast milk and should not be used while breastfeeding.
Medically reviewed by Eni Williams, PharmD
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.